Literature DB >> 27398141

Identification a novel tumor-suppressive hsa-miR-599 regulates cells proliferation, migration and invasion by targeting oncogenic MYC in hepatocellular carcinoma.

Jingjing Tian1, Xibao Hu2, Wei Gao1, Jie Zhang1, Ming Chen1, Xinrong Zhang1, Junhong Ma1, Hongxia Yuan3.   

Abstract

Increasing evidences have demonstrated that microRNAs (miRNAs) act an essential role in regulating tumor progression and metastasis. Previous miRNAs microarray data showed that hsa-miR-599 is lower expressed in hepatocellular carcinoma (HCC); however, the function and molecular mechanism of hsa-miR-599 on HCC has not been well illustrated. Here, we first analyzed the expression level of hsa-miR-599 in HCC tissues and cell lines by real-time reverse-transcription PCR (qRT-PCR). Interestingly, we found that hsa-miR-599 was significantly down-regulated in the examined HCC tissues and cell lines. Then cells proliferation, migration and invasion were assessed by MTT, wound-healing and trans-well assay respectively. The results showed that over-expression of hsa-miR-599 resulted in inhibited HCC cells proliferation, migration and invasion in vitro. In addition, dual-luciferase reporter assay, qRT-PCR and Western blot analyzes were used to confirm MYC (v-myc avian myelocytomatosis viral oncogene homolog) as a target gene of hsa-miR-599. MYC expression was up-regulated in HCC tissues and cell lines, and restoration of hsa-miR-599 could remarkably decreased the mRNA and protein levels of MYC. Moreover, over-expression of MYC partly reversed hsa-miR-599-mediated inhibition of HCC cells proliferation, migration and invasion in vitro. Taken together, our data demonstrate that hsa-miR-599 acts as a tumor suppressor and inhibits HCC cells proliferation, migration and invasion by partly targeting oncogenic MYC, which hints that hsa-miR-599 can be a diagnostic and therapeutic biomarker in HCC.

Entities:  

Keywords:  Hsa-miR-599; MYC; hepatocellular carcinoma; suppressor

Year:  2016        PMID: 27398141      PMCID: PMC4931152     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  28 in total

1.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

2.  The IκB family member Bcl-3 stabilizes c-Myc in colorectal cancer.

Authors:  Zhanjie Liu; Yuhang Jiang; Yinyong Hou; Yiming Hu; Xinwei Cao; Yu Tao; Chen Xu; Sanhong Liu; Shouli Wang; Lunshan Wang; Yufang Shi; Ulrich Siebenlist; Xiaoren Zhang
Journal:  J Mol Cell Biol       Date:  2013-06-20       Impact factor: 6.216

3.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Authors:  Sandrine Boyault; David S Rickman; Aurélien de Reyniès; Charles Balabaud; Sandra Rebouissou; Emmanuelle Jeannot; Aurélie Hérault; Jean Saric; Jacques Belghiti; Dominique Franco; Paulette Bioulac-Sage; Pierre Laurent-Puig; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

4.  MicroRNA-205 regulates ubiquitin specific peptidase 7 protein expression in hepatocellular carcinoma cells.

Authors:  Liang Zhu; Rong Liu; Wei Zhang; Sheng Qian; Jian-Hua Wang
Journal:  Mol Med Rep       Date:  2015-06-25       Impact factor: 2.952

5.  MiR-491 attenuates cancer stem cells-like properties of hepatocellular carcinoma by inhibition of GIT-1/NF-κB-mediated EMT.

Authors:  Xiaojun Yang; Jing Ye; Han Yan; Zhaoyang Tang; Jian Shen; Jianping Zhang; Lihua Yang
Journal:  Tumour Biol       Date:  2015-07-19

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

7.  Metformin targets c-MYC oncogene to prevent prostate cancer.

Authors:  Tunde Akinyeke; Satoko Matsumura; Xinying Wang; Yingjie Wu; Eric D Schalfer; Anjana Saxena; Wenbo Yan; Susan K Logan; Xin Li
Journal:  Carcinogenesis       Date:  2013-10-15       Impact factor: 4.944

8.  MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma.

Authors:  Wei Zhang; Kai Liu; Songyang Liu; Bai Ji; Yingchao Wang; Yahui Liu
Journal:  Tumour Biol       Date:  2015-07-10

9.  Construction of HCC-targeting artificial miRNAs using natural miRNA precursors.

Authors:  Xiaoming Huang; Zhenyu Jia
Journal:  Exp Ther Med       Date:  2013-05-14       Impact factor: 2.447

10.  Comparison of hepatocellular carcinoma miRNA expression profiling as evaluated by next generation sequencing and microarray.

Authors:  Yoshiki Murakami; Toshihito Tanahashi; Rina Okada; Hidenori Toyoda; Takashi Kumada; Masaru Enomoto; Akihiro Tamori; Norifumi Kawada; Y-h Taguchi; Takeshi Azuma
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

View more
  9 in total

1.  A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer.

Authors:  James Saller; Kun Jiang; Yin Xiong; Sean J Yoder; Kevin Neill; Jose M Pimiento; Luis Pena; F Scott Corbett; Anthony Magliocco; Domenico Coppola
Journal:  Dig Dis Sci       Date:  2021-03-13       Impact factor: 3.199

2.  Diagnostic significance and potential function of miR-338-5p in hepatocellular carcinoma: A bioinformatics study with microarray and RNA sequencing data.

Authors:  Liang Liang; Li Gao; Xiao-Ping Zou; Meng-Lan Huang; Gang Chen; Jian-Jun Li; Xiao-Yong Cai
Journal:  Mol Med Rep       Date:  2017-11-21       Impact factor: 2.952

3.  Hsa-miR-599 suppresses the migration and invasion by targeting BRD4 in breast cancer.

Authors:  Yonghui Wang; Yana Sui; Qinwei Zhu; Xiaomei Sui
Journal:  Oncol Lett       Date:  2017-07-21       Impact factor: 2.967

4.  DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma.

Authors:  Junyu Long; Peipei Chen; Jianzhen Lin; Yi Bai; Xu Yang; Jin Bian; Yu Lin; Dongxu Wang; Xiaobo Yang; Yongchang Zheng; Xinting Sang; Haitao Zhao
Journal:  Theranostics       Date:  2019-09-25       Impact factor: 11.556

5.  MiR-599 Protects Cardiomyocytes against Oxidative Stress-Induced Pyroptosis.

Authors:  Xiaoying Fan; Enbo Zhan; Yuan Yao; Ruoxi Zhang; Yong Sun; Xuefeng Tian
Journal:  Biomed Res Int       Date:  2021-02-18       Impact factor: 3.411

6.  Identification of a circRNA-miRNA-mRNA regulatory network for exploring novel therapeutic options for glioma.

Authors:  Yi He; Yihong Chen; Yuxin Tong; Wenyong Long; Qing Liu
Journal:  PeerJ       Date:  2021-08-06       Impact factor: 2.984

7.  Clinical and Diagnostic Significance of Homer1 in hepatitis B virus-induced Hepatocellular Carcinoma.

Authors:  Ping Luo; Xiaobo Feng; Wei Jing; Man Zhu; Nandi Li; Hu Zhou; Paul F Worley; Hongyan Chai; Jiancheng Tu
Journal:  J Cancer       Date:  2018-01-11       Impact factor: 4.207

8.  Bioinformatics analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma.

Authors:  Liang Sang; Xue-Mei Wang; Dong-Yang Xu; Wen-Jing Zhao
Journal:  World J Gastroenterol       Date:  2018-06-28       Impact factor: 5.742

9.  Hsa_circ_0006916 Knockdown Represses the Development of Hepatocellular Carcinoma via Modulating miR-599/SRSF2 Axis.

Authors:  Zhixiang Zhu; Songhe Shen; Sen Zhao; Zhixue Wang
Journal:  Onco Targets Ther       Date:  2020-11-04       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.